TITLE

The co-occurrence of genetic variants in the *TYR* and *OCA2* genes confers

susceptibility to albinism

AUTHOR LIST & AFFILIATIONS

David J. Green[1], Vincent Michaud[2,3], Eulalie Lasseaux[2], Claudio Plaisant[2], UK

Biobank Eye and Vision Consortium, Tomas Fitzgerald[4], Ewan Birney[4], Graeme C.

Black[1,5,#], Benoît Arveiler[2,3,#], Panagiotis I. Sergouniotis[1,4,5,6]

[1] Division of Evolution, Infection and Genomics, School of Biological Sciences,

Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.

[2] Department of Medical Genetics, University Hospital of Bordeaux, Bordeaux,

France.

[3] INSERM U1211, Rare Diseases, Genetics and Metabolism, University of

Bordeaux, Bordeaux, France.

[4] European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-

EBI), Wellcome Genome Campus, Cambridge, UK.

[5] Manchester Centre for Genomic Medicine, Saint Mary's Hospital, Manchester

University NHS Foundation Trust, Manchester, UK.

[6] Manchester Royal Eye Hospital, Manchester University NHS Foundation Trust,

Manchester, UK.

# These authors contributed equally: Graeme C. Black, Benoît Arveiler

Correspondence to

Panagiotis I. Sergouniotis (panagiotis.sergouniotis@manchester.ac.uk).

ABSTRACT

Although rare genetic conditions are mostly caused by DNA sequence alterations

that functionally disrupt individual genes, large-scale studies using genome

sequencing have started to unmask additional complexity. Understanding how

combinations of variants in different genes shape human phenotypes is expected to

provide important insights into the clinical and genetic heterogeneity of rare

disorders. We used albinism, an archetypal rare condition associated with

hypopigmentation, as an exemplar for the study of genetic interactions. We analysed

data from the Genomics England 100,000 Genomes Project alongside a cohort of

1,120 individuals with albinism, and investigated the effect of dual heterozygosity for

the combination of two established albinism-related variants: *TYR*:c.1205G>A

(p.Arg402Gln) [rs1126809] and *OCA2*:c.1327G>A (p.Val443Ile) [rs74653330]. As

each of these changes alone is insufficient to cause disease when present in the

heterozygous state, we sought evidence of synergistic effects. We found that, when

both variants are present, the probability of receiving a diagnosis of albinism is

significantly increased (odds ratio 14.0; 95% confidence interval 6.8 – 26.5; p-value

1.9×10^{-9}). Further analyses in an independent cohort, the UK Biobank, supported

this finding and highlighted that heterozygosity for the *TYR*:c.1205G>A and

OCA2:c.1327G>A variant combination is associated with statistically significant

alterations in visual acuity and central retinal thickness (traits that are considered

albinism endophenotypes). The approach discussed in this report opens up new

avenues for the investigation of oligogenic patterns in apparently Mendelian

disorders.

KEYWORDS: epistasis, digenic, oligogenic, bi-locus, genetic interaction

MAIN TEXT

INTRODUCTION

An individual affected by a condition that appears to segregate as a Mendelian trait, would be expected to carry large-effect genetic variation in a single gene/locus. However, for a significant proportion of affected probands, single-gene-centric genomic analyses fail to identify a clear genetic diagnosis.[1-6] Although this diagnostic and knowledge gap is, to a degree, due to imperfect phenotyping, sequencing or annotation, other factors may be contributing. There is for example growing evidence supporting the hypothesis that many apparently Mendelian phenotypes are caused by the interaction of multiple variants in more than one locus.[7-11] Uncovering such genetic interactions has the potential to provide insights not only into disease mechanisms and diagnostics but also into phenomena like incomplete penetrance and variable expressivity.[12-14]

There are many patterns through which genetic changes in more than one gene can synergistically shape a phenotype. A simple scenario, would involve two heterozygous variants in two distinct loci cooperating to mediate disease (when each individual variant in isolation fails to explain the clinical presentation). Only a small number of cases with this specific form of digenic inheritance have been described[15-17], the majority detected through qualitative approaches involving variant segregation analyses in a small number of families. In these cases, interaction-based models have generally been used to provide a post hoc explanation of the observed phenomena. By contrast, we describe a quantitative, case-control approach that allows obtaining statistical evidence of digenic patterns. We focused on specific genotypes in the *TYR* and *OCA2* genes; biallelic variants in each of these two genes

are associated with albinism, a clinically and genetically heterogeneous group of

conditions characterised by reduced levels of melanin pigment. Key features of

albinism include visual abnormalities and under-development of the central retina

(*i.e.* the fovea); skin and/or hair hypopigmentation may also be present.[18] Building on

recent work[19-22], we aimed to advance our understanding of the genetic complexity

of this rare disorder.

RESULTS & DISCUSSION

A cohort of 1,015 people with albinism underwent testing of ≤19 albinism-related

genes; these individuals were not known to be related and had predominantly

European-like ancestries (Supplementary Data 1). A further 105 probands with

albinism were identified in the Genomics England 100,000 Genomes Project

dataset.[23] A "control" cohort of 29,451 unrelated individuals that had no recorded

diagnosis or features of albinism was also identified in this resource (Fig.1,

Supplementary Table 1, Methods).

Figure 1. Outline of the case-control study design.

A case-control analysis was performed to gain insights into the role of genotypes involving dual heterozygosity for *TYR*:c.1205G>A (p.Arg402Gln) [rs1126809] and *OCA2*:c.1327G>A (p.Val443Ile) [rs74653330] in albinism. These two missense changes were selected as they are the commonest albinism-related variants in European-like populations.

The majority of participants in the "case" cohort (1,015/1,120) were identified through the database of the University Hospital of Bordeaux Molecular Genetics Laboratory, France. All these probands had at least one key ocular feature of albinism, *i.e.* nystagmus or prominent foveal hypoplasia. The remaining 105/1,120 cases were identified through the Genomics England 100,000 Genomes Project dataset and had a diagnosis of albinism or partial/ocular albinism. The "control" cohort included 29,451 unrelated individuals from the Genomics England 100,000 Genomes Project dataset, none of whom had a recorded diagnosis of albinism.

To reduce the likelihood of obtaining spurious signals due to population stratification effects or due to the presence of albinism-related variants other than the two studied changes, we focused only on individuals who: (i) were projected to have European-like ancestries; (ii) did not have a genotype in keeping with a molecular diagnosis of albinism; (iii) were not heterozygous for a pathogenic or a likely pathogenic variant in *TYR* or *OCA2* (excluding *TYR*:c.1205G>A and *OCA2*:c.1327G>A). The following two covariates were used: sex and number of common albinism-associated alleles, *i.e.* DNA sequence alterations in the genomic locations corresponding to *TYR*:c.−301C>T [rs4547091] and *TYR*:c.575C>A (p.Ser192Tyr) [rs1042602]. These two variants have been previously shown to modify the effect of *TYR*:c.1205G>A which is a common missense change that can act as a "hypomorphic" variant.[19-21]

To assess the robustness of the findings we performed additional analyses in subsets of the cohort. Validation studies in an independent cohort (UK Biobank) were also conducted.

100K_GP, Genomics England 100,000 Genomes Project; HGMD, Human Gene Mutation Database v2021.2; het, heterozygous; UKB, UK Biobank. *TYR* and *OCA2* variant numbering was based on the transcripts with the following identifiers: NM_000372.5/ENST00000263321.6. and NM_000275.3/ENST00000354638.8.

Searching for genetic elements underlying digenic traits may be carried out at the

level of genes, genotypes or DNA variants. It is noted that a given pair of DNA

variants comprises up to nine pairs of genotypes while a given gene may contain a

large number of variants. Each of these search strategies has inherent advantages

and pitfalls.[24] We opted for a genotype-based approach that offers a high level of

precision and is more likely to provide insights that can be used for clinical genome

interpretation.

Our genotype-based analysis focused on two prevalent albinism-related changes,

TYR:c.1205G>A (p.Arg402Gln) [rs1126809] and *OCA2*:c.1327G>A (p.Val443Ile)

[rs74653330]. We hypothesised that when these two missense variants are both

present in the heterozygous state ("dual heterozygosity"), their interaction is driving

the pathology observed in albinism. Notably, both these changes have been shown

to reduce the activity of their respective protein products *in vitro*.[25-29] Further,

previous studies have pointed to a functional interaction between the TYR and OCA2

proteins: the latter has a role in the pH regulation of the melanosome which, in turn,

can affect the catalytic activity of the former (*i.e.* tyrosinase, the rate-limiting enzyme

for the synthesis of melanin in the melanosomes of retinal pigment epithelia and

melanocytes).[18,30] Both *TYR*:c.1205G>A and *OCA2*:c.1327G>A have been

implicated in albinism when *in trans* with pathogenic changes in the same gene.[21,31]

Also, multiple associations have been recorded for these two variants including with

skin/hair pigmentation and skin cancer.[32] It is noted that these two changes were

chosen as they are the two commonest albinism-related variants in populations of

European-like ancestries, a feature that can help mitigate potential issues with

statistical power. It is also highlighted that the minor allele frequencies of the

TYR:c.1205G>A and *OCA2*:c.1327G>A changes in European populations are 27%

and 0.3% respectively (Non-Finnish European subset of the Genome Aggregation

Database [gnomAD] v2.1.1).[33] The particularly common *TYR*:c.1205G>A change

has been associated with incomplete penetrance (and variable expressivity), and

previous studies have pointed to the potential for other *TYR* variants to modify its

effect.[19-21,25,34-36]

We used Firth regression analysis[37,38] to study how dual heterozygosity for

TYR:c.1205G>A and *OCA2*:c.1327G>A affects the probability of receiving a

diagnosis of albinism ("risk of albinism"). This logistic regression approach has been

designed to handle small, imbalanced datasets (which are common in studies of rare

conditions) and allows for adjustment of key covariates (which is not possible in

contingency table methods) (Fig.1). To increase the genetic similarity[39] between the

compared cohorts (cases and controls) and to reduce the impact of albinism-related

variants other than the two studied changes (*TYR*:c.1205G>A and

OCA2:c.1327G>A), we excluded from our analysis individuals that: (i) did not have

European-like ancestries, (ii) were found to have genotypes in keeping with a

molecular diagnosis of albinism, (iii) carried pathogenic or likely pathogenic variants

in the *TYR* or *OCA2* gene (with the exception of *TYR*:c.1205G>A and

OCA2:c.1327G>A). The resulting case and control cohorts included 205 and 20,350

individuals respectively. These were used to perform case-control comparisons

between the following genotype groups:

- *group A* (reference group): homozygous for *TYR*:c.1205= and *OCA2*:c.1327=

- *group B* (single *TYR* heterozygote group): heterozygous for *TYR*:c.1205G>A and
homozygous for *OCA2*:c.1327=.

- *group C* (single *OCA2* heterozygote group): homozygous for *TYR*:c.1205G= and
heterozygous for *OCA2*:c.1327G>A.

- *group D* (dual heterozygote group): heterozygous for the *TYR*:c.1205G>A and
OCA2:c.1327G>A variant combination.

These groups correspond to different levels of dysfunction of the OCA2 and TYR

molecules and the findings of the regression analysis revealed a synergistic

potentiation of the changes at the two loci (Fig.2, Supplementary Figure 1a and

Supplementary Table 2). The point estimate for the odds of receiving a diagnosis of

albinism in individuals who are heterozygous for the *TYR*:c.1205G>A and

OCA2:c.1327G>A variant combination was 14.0 (the 95% confidence interval was

6.8 – 26.5 and the p-value was 1.9×10^{-9}).

Figure 2. The combination of the *TYR*:c.1205G>A (p.Arg402Gln) and *OCA2*:c.1327G>A (p.Val443Ile) variants in a dual heterozygous state confers susceptibility to albinism.

The probability of receiving a diagnosis of albinism (*i.e.* the risk of albinism) was calculated for the following genotype groups:

- ***group A*** (reference group): homozygous for *TYR*:c.1205= and *OCA2*:c.1327=
- ***group B*** (single *TYR* heterozygote group): heterozygous for *TYR*:c.1205G>A and homozygous for *OCA2*:c.1327=
- ***group C*** (single *OCA2* heterozygote group): homozygous for *TYR*:c.1205G= and heterozygous for *OCA2*:c.1327G>A
- ***group D*** (dual heterozygote group): heterozygous for the *TYR*:c.1205G>A and *OCA2*:c.1327G>A variant combination.

A $\log_{10}$ scale is used. The circle in the middle of each horizontal line (95% confidence interval) represents the point estimate of each odds ratio. Group A was used as the reference group to which all other groups were compared using Firth regression analysis (*i.e.* the odds ratio for this group was fixed at 1). Further information including numerical data can be found in Supplementary Table 2.

To increase confidence in these observations, we performed additional analyses in

an independent cohort, the UK Biobank.[40] We found that UK Biobank volunteers who

were heterozygous for the *TYR*:c.1205G>A and *OCA2*:c.1327G>A variant

combination had not only a higher chance of receiving a diagnosis of albinism

(OR>3.1, p-value=0.003) but also had, on average, slightly worse visual acuity and

marginally thicker central retina (the respective Kruskal-Wallis p-values were 2.5 x

10^{-6} and 6.3 x 10^{-5}; Fig.3 and Supplementary Tables 3 and 4). It is noted that visual

acuity and central retinal thickness are quantitative endophenotypes of albinism and

these findings suggest that the studied *TYR*/*OCA2* variant combination is both

contributing to the genetic architecture of albinism and having a role in the

development of the visual system in individuals from the general population.

Figure 3. The combination of the *TYR*:c.1205G>A (p.Arg402Gln) and *OCA2*:c.1327G>A (p.Val443Ile) variants in a dual heterozygous state is associated with (a) a higher probability of receiving an albinism diagnosis (*i.e.* a higher risk of albinism), (b) lower visual acuity and (c) increased central retinal thickness in UK Biobank participants.

The following genotype groups were studied:

- *group A* (reference group): homozygous for *TYR*:c.1205= and *OCA2*:c.1327=
- *group B* (single *TYR* heterozygote group): heterozygous for *TYR*:c.1205G>A and homozygous for *OCA2*:c.1327=
- *group C* (single *OCA2* heterozygote group): homozygous for *TYR*:c.1205G= and heterozygous for *OCA2*:c.1327G>A
- *group D* (dual heterozygote group): heterozygous for the *TYR*:c.1205G>A and *OCA2*:c.1327G>A variant combination.

It is noted that individuals with albinism tend to have reduced visual acuity (*i.e.* higher LogMAR value than 0.2) and increased central retinal thickness (due to underdevelopment of the fovea). Further information including numerical data can be found in Supplementary Tables 3 and 4.

We provide evidence that the *TYR*:c.1205G>A and *OCA2*:c.1327G>A changes

appear to have a joint effect when each is encountered in the heterozygous state.

However, the interpretation of this variant combination in clinical diagnostic settings

should be approached cautiously. Although the detected effect size (odds ratio) is

significant, it would be more in keeping with a predisposing[41] rather than a

pathogenic[42] genotype. Further, while it is tempting to view our observations as an

example of a digenic pattern, this would have reductionist connotations; interactions

are ubiquitous in nature and we expect that increased sample sizes will elucidate

longer "chains" of interconnected genetic variation. It is thus plausible that the effect

size of the studied genotype will increase when further genetic changes that impact

on tyrosinase function or melanosome pH are added to the model. Indeed,

observations in the presented data already point to this possibility (Supplementary

Data 2 and 3).

One limitation of this study is our inability to match stringently the albinism cases with

the unaffected controls, especially in terms of genetic background.[43] Although recent

ancestry was considered, our analysis was imperfect as it was not possible to

reliably assign genetic ancestry to most albinism cases. We used a combination of

orthogonal approaches to evaluate the robustness and generalisability of our

findings. First, we used 35 presumed neutral single-nucleotide variants to calculate

the genomic inflation factor lambda (λGC)[44,45]; the λ_{median} was found to be 1.04, in

keeping with limited confounding by ancestry (Supplementary Table 5).

Subsequently, we performed a targeted secondary analysis using only Genomics

England 100,000 Genomes Project data which allowed us to study case and control

groups of high genetic similarity. The results supported our key findings and

increased confidence in the validity of the detected associations (Supplementary

Fig.1b and Supplementary Table 6). Another potential caveat is that the detected

signal in dual heterozygotes for *TYR*:c.1205G>A and *OCA2*:c.1327G>A could, to a

degree, be driven by undetected pathogenic variation in either *TYR* or *OCA2*. This

cannot be excluded despite the fact that medical-grade genetic analyses were

undertaken. It can be argued however that significant confounding is unlikely

especially given that the effect of dual heterozygosity for *TYR*:c.1205G>A and

OCA2:c.1327G>A appears to be greater than that of genotypes involving

heterozygosity for either *TYR*:c.1205G>A or *OCA2*:c.1327G>A alone

(Supplementary Table 2, 3, 6 and 7).

In conclusion, we have shown that dual heterozygosity for a *TYR* and an *OCA2*

variant confers susceptibility to albinism. Shedding light into this and other variant

interactions is expected to increase our understanding of the pathways and cellular

processes affected in albinism. Notably, the concepts discussed herein are likely to

be relevant to other rare disorders, and systems-based approaches using biological

modules are expected to narrow the molecular diagnostic gap. Future work will focus

on increasing sample sizes, embracing more diverse populations and searching for

high-order interactions by considering more than two variants at a time.

METHODS

Cohort characteristics and genotyping

University Hospital of Bordeaux albinism cohort

Individuals with albinism were identified through the database of the University Hospital of Bordeaux Molecular Genetics Laboratory, France. This is a national reference laboratory that has been performing genetic testing for albinism since 2003 and has been receiving samples from individuals predominantly based in France (or French-administered overseas territories).

Information on the dermatological and ophthalmological phenotypes was available for all affected individuals, and each of these cases had at least one of the key ocular features of albinism, *i.e.* infantile nystagmus or absence of a foveal pit (prominent foveal hypoplasia). No pre-screening based on genotype was undertaken other than selecting individuals in whom position c.-301 of *TYR* was sequenced. Only individuals who were not knowingly related were included.

Genetic testing, bioinformatic analyses, and variant interpretation were performed as previously described.[20,21] Briefly, most participants had gene-panel testing of ≤19 genes associated with albinism (*TYR*, *OCA2*, *TYRP1*, *SLC45A2*, *SLC24A5*, *C10ORF11*, *GPR143*, *HPS 1* to *10*, *LYST*, *SLC38A8*) using IonTorrent platforms. High-resolution array-CGH (comparative genomic hybridization) was used to detect copy number variants in these genes. All genetic changes of interest were confirmed with an alternative method (e.g. Sanger sequencing or quantitative PCR). Clinical interpretation of variants was performed using criteria consistent with the 2015 American College of Medical Genetics and Genomics (ACMG) best practice guidelines.[42] It is noted that genetic findings in this cohort have been partly reported in previous publications from our group.[19,22]

Due to the limited number of genomic locations screened in this cohort, it was not possible to reliably assess genetic ancestry and to "objectively" assign individuals to genetic ancestry groups. Attempting to mitigate this, we processed available data on self-identified ethnicity that were collected through questionnaires. Responses were inspected and stratification into five broad continental groups (European, African, Admixed American, East Asian, South Asian) was performed.

Genomics England 100,000 Genomes Project cohort

Clinical and genomic data from the Genomics England 100,000 Genomes Project were accessed

through a secure Research Environment that is available to registered users. This dataset was

collected as part of a national genome sequencing initiative.[46] Enrolment was coordinated by

Genomics England Limited, and participants were recruited mainly at National Health Service (NHS)

Hospitals in the UK.[23] Clinical information was recorded in Human Phenotype Ontology (HPO)[47] terms

and International Classification of Diseases (ICD) codes. Genome sequencing was performed in DNA

samples from ≥78,195 individuals using Illumina HiSeq X systems (150 base-pair paired-end format).

Reads were aligned using the iSAAC Aligner v03.16.02.19 and small variants were called using

Starling v2.4.7.[48] Structural variants and long indel (>50bp) calling was performed with Manta v0.28.0,

and copy number variants (CNVs) were called with Canvas v1.3.1.[49,50] Aggregation of single-sample

gVCFs was performed using the Illumina software gVCF genotyper v2019.02.29;

normalisation/decomposition was implemented by vt v0.57721[51]. The multi-sample VCF was then split

into 1,371 roughly equal chunks to allow faster processing and the loci of interest were queried using

bcftools v1.9[52] (see https://research-help.genomicsengland.co.uk/display/GERE/ for further

information). Only variants that passed standard quality control criteria were processed (including the

criteria discussed in https://re-docs.genomicsengland.co.uk/site_qc/ and criteria analogous to those

outlined in https://re-docs.genomicsengland.co.uk/somatic_sv/#note-on-variant-calling). In addition,

we filtered out genotypes with: genotype score <20; read depth <10; allele balance <0.2 and >0.8 for

heterozygotes; allele balance >0.1 or <0.9 for homozygotes (reference and alternate, respectively).

Genomic annotation was performed using Ensembl VEP[53]. Variants with a "total" minor allele

frequency (MAF) <1% in the Genome Aggregation Database (gnomAD v2.1.1)[33] and a "disease-

causing" (DM) label in HGMD v2021.2[54] were flagged (and are hitherto referred to as "HGMD-listed

variants"). In depth manual curation of all detected rare (*i.e.* MAF < 1%) variants in *TYR* and *OCA2*

was undertaken and these changes were classified according to the 2015 American College of

Medical Genetics and Genomics (ACMG) best practice guidelines.[42]

Ancestry inference was performed in the Genomics England 100,000 Genomes Project cohort using

principal component analysis. Data from the 1000 genomes project (phase 3) dataset were used and

five broad super-populations were projected (European, African, Admixed American, East Asian,

South Asian) (further information on this can be found online at https://research-

help.genomicsengland.co.uk/display/GERE/Ancestry+inference).

We focused on a pre-determined subset of the Genomics England 100,000 Genomes Project dataset

that includes only unrelated probands (n=29,556). Of these, 105 had a diagnosis of albinism, *i.e.* the

ICD-10 term "Albinism" [E70.3] and/or the HPO terms "Albinism" [HP:0001022], "Partial albinism"

[HP:0007443] or "Ocular albinism" [HP:0001107] were assigned. Together with the University Hospital

of Bordeaux cases, these 105 probands formed the "case" cohort. The remaining 29,451 probands

had no recorded diagnosis or phenotypic features of albinism and formed the "control" cohort. We

note that comprehensive ophthalmic phenotyping was not routinely undertaken in Genomics England

100,000 Genomes Project participants. We cannot therefore be certain that a small number of

individuals with mild/subclinical forms of albinism are not included in the control cohort.

Case-control analysis to estimate the probability of an albinism diagnosis

The effect of dual heterozygosity for *TYR:*c.1205G>A (p.Arg402Gln) [rs1126809] and

*OCA2:*c.1327G>A (p.Val443Ile) [rs74653330] on the probability of receiving a diagnosis of albinism

(*i.e.* the albinism risk) was estimated using data from the University Hospital of Bordeaux albinism

cohort and the Genomics England 100,000 Genomes Project dataset. A case-control analysis of a

binary trait (presence/absence of albinism) was conducted assuming a recessive model. Logistic

regression using the Firth bias reduction method[37,38] was utilised (as implemented in "logistf" R

package). The following parameters were set:

• inclusion criteria: the analysis was conducted only on study subjects who: (i) were projected to

have European-like ancestries, (ii) were not found to have genotypes in keeping with a molecular

diagnosis of albinism, (iii) carried no pathogenic or likely pathogenic variants in the *TYR* or *OCA2*

gene (with the exception of the two studied changes *TYR*:c.1205G>A and *OCA2*:c.1327G>A).

• covariates: sex; number of common albinism-associated alleles (see relevant sub-section below).

Ancestry: To increase the genetic similarity between the studied case and control cohorts, we focused

on individuals who were likely to fall within the same broad ancestral group. It is highlighted though

that the utilised approach was imperfect as it was not possible to objectively determine genetic

ancestry in individuals from the University Hospital of Bordeaux albinism cohort (as mentioned above,

self-identified ethnicity was instead used as a surrogate). Confounding by ancestry (*i.e.* population

stratification) is therefore a possibility.[39] We attempted to quantify this by calculating the genomic

inflation factor lambda (λGC). A total of 35 single-nucleotide variants were selected using a previously

described approach (see Supplementary Table 5 and [18]). Case-control comparisons were then made

for each of these 35 λGC markers using Firth regression analysis. The resulting test statistics were

used to calculate the median value of λGC.[18]

Albinism-related genotypes: To reduce the likelihood of obtaining spurious results due to the impact of

albinism-related variants other than the two studied changes (*TYR*:c.1205G>A and

OCA2:c.1327G>A), we excluded individuals who carried genotypes consistent with a molecular

diagnosis of albinism. This included study subjects with:

• homozygous pathogenic or likely pathogenic HGMD-listed variants in autosomal albinism-related

genes *(TYR, OCA2, TYRP1, SLC45A2, SLC24A5, C10ORF11, HPS 1* to *10, LYST, SLC38A8)*,

• presumed biallelic pathogenic or likely pathogenic HGMD-listed variants in autosomal albinism-

related genes *(TYR, OCA2, TYRP1, SLC45A2, SLC24A5, C10ORF11, HPS 1* to *10, LYST,*

SLC38A8),

• hemizygous pathogenic or likely pathogenic HGMD-listed variants in *GPR143* or *FRMD7,*

• the *TYR* c.[-301C;575C>A;1205G>A] or *TYR* c.[-301C;575C;1205G>A] albinism-related

haplotype[19] in homozygous state

• the *TYR* c.[-301C;575C>A;1205G>A] or *TYR* c.[-301C;575C;1205G>A] albinism-related

haplotype in heterozygous state plus a heterozygous pathogenic or likely pathogenic variant in

TYR.

We also excluded from our analysis individuals who were found to carry pathogenic or likely

pathogenic variants in the *TYR* or *OCA2* gene (in heterozygous state). Small scale genetic changes

(with the exception of *TYR*:c.1205G>A and *OCA2*:c.1327G>A), copy number and structural variants

were factored in.

Common albinism-associated alleles: The effect of one of the studied changes (*TYR* c.1205G>A) has

been previously shown to be modified by the following two variants[19-21,25,34-36] which have been added

as a covariate to the regression model:

• *TYR* c.-301C>T [rs4547091], located in the *TYR* promoter; the derived, non-ancestral allele c.-301C

(or c.-301=) has a MAF of ~60% in non-Finnish European (NFE) populations in the Genome

Aggregation Database (gnomAD v2.1.1)[33];

• *TYR* c.575C>A (p.Ser192Tyr) [rs1042602], which has a MAF of ~36% in gnomAD NFE populations.

It is highlighted that the *TYR* c.-301= and the *TYR* c.575C>A (p.Ser192Tyr) alleles are frequently found

in linkage disequilibrium so the presence of the latter would, in most cases, suggest the presence of

the former on the same haplotype.

Case-control comparisons between TYR/OCA2 genotype groups: Our primary analysis focused on

performing case-control comparisons between groups of genotypes that include different alleles at

positions *TYR*:c.1205 and *OCA2*:c.1327. These groups were:

• group A (reference group): homozygous for *TYR*:c.1205= and *OCA2*:c.1327=

• group B (single TYR heterozygote group): heterozygous for *TYR*:c.1205G>A and homozygous for

OCA2:c.1327=.

• group C (single OCA2 heterozygote group): homozygous for *TYR*:c.1205G= and heterozygous for

OCA2:c.1327G>A.

• group D (dual heterozygote group): heterozygous for the *TYR*:c.1205G>A and *OCA2*:c.1327G>A

variant combination.

Analyses were also conducted in individuals who were found to be homozygous for *TYR*:c.1205G>A

(but are considered unsolved, *i.e.* they do not carry the *TYR* c.575C>A or the *TYR* c.-301= variant in

the homozygous state); these were split into two groups:

• *group E:* homozygous for *TYR*:c.1205G>A and *OCA2*:c.1327=;

• *group F:* homozygous for *TYR*:c.1205G>A and heterozygous for OCA2:c.1327G>A

Group A was used as the reference group to which all other groups were compared using Firth

regression analysis (*i.e.* the odds ratio for this group was fixed at 1).

The primary analysis focused on a mixed case cohort (including 174 probands from the University

Hospital of Bordeaux cohort and 31 cases from the Genomics England 100,000 Genomes Project

dataset) and a control cohort from the Genomics England 100,000 Genomes Project dataset (20,350

unrelated individuals) (Fig.2; Supplementary Fig.1a; Supplementary Table 2). A secondary analysis

focusing only on individuals from the Genomics England 100,000 Genomes Project dataset (31

cases, 20,350 controls) was also undertaken (Supplementary Fig.1b; Supplementary Table 6).

Replication of findings in the UK Biobank cohort

The effect of dual heterozygosity for *TYR:*c.1205G>A and *OCA2:*c.1327G>A was studied in the UK

Biobank. UK Biobank is a biomedical resource containing in-depth genetic and health information

from >500,000 individuals from across the UK.[40] A subset of UK Biobank volunteers underwent

enhanced phenotyping including visual acuity testing (131,985 individuals) and imaging of the central

retina (84,748 individuals)[55]; the latter was obtained using optical coherence tomography (OCT), a

non-invasive imaging test that rapidly generates cross-sectional retinal scans at micrometre-

resolution.[56,57] All UK Biobank volunteers whose data were analysed as part of this study were

imaged using the 3D OCT-1000 Mark II device (Topcon, Japan); the relevant methodology has been

previously described.[55] Notably, only 24 UK Biobank participants have been assigned a diagnosis of

albinism (data field 41270; ICD-10 term "Albinism" [E70.3]) of which only 7 had visual acuity

measurements and none had OCT imaging; 19 additional individuals had a diagnosis of albinism in

their primary care record data (resource 591).

Aiming to assess the robustness of the results in the combined University Hospital of Bordeaux and

Genomics England 100,000 Genomes Project dataset, we performed case-control analyses in UK

Biobank volunteers. First, genotyping array data were used to obtain genotypes for the

*TYR:*c.1205G>A variant (data field 22418 including information from the Applied Biosystems UK

Biobank Axiom Array containing 825,927 markers). In contrast to this change, the *OCA2:*c.1327G>A

variant was not directly captured by the array. However, high-quality (>99.9%) imputation data were

available (data field 22828). Only individuals successfully genotyped at both sites were retained.

Firth regression analysis was subsequently used to perform comparisons between genotype groups

A-D. Only individuals who were estimated by principal component analysis to have European-like

ancestries (data field 22006) were included in this analysis; sex and the number of common albinism-

associated alleles were used as covariates (Fig.3a; Supplementary Table 3).

Given that reduced visual acuity and increased central retinal thickness (due to underdevelopment of

the fovea) are two hallmark features of albinism we investigated the impact of selected *TYR/OCA2*

variant combinations on these two quantitative traits.

We first obtained data on the left LogMAR visual acuity for UK Biobank volunteers (data field 5201,

"instance 0" datasets). These visual acuity measurements were then used to compare visual

performance between groups of volunteers with selected *TYR/OCA2* genotype combinations

(genotype groups A-D). As the obtained distributions deviated from normality, the Kruskal-Wallis test

was used. Pair-wise comparisons were performed and the p-values were adjusted using the

Benjamini-Hochberg method (Fig.3b; Supplementary Table 4).

We then obtained central retinal thickness measurements from UK Biobank OCT images using the

"macular thickness at the central subfield" data field (27802; defined as the average distance between

the hyperreflective bands corresponding to the RPE and the internal limiting membrane (ILM), across

the central 1 mm diameter circle of the ETDRS grid) for UK Biobank volunteers.[58] The obtained

measurements were subsequently used to compare central retinal thickness between groups of UK

Biobank volunteers with selected *TYR/OCA2* genotype combinations (groups A-D). As some of the

obtained distributions deviated from normality, the Kruskal-Wallis test was used. Pair-wise

comparisons were performed and the p-values were adjusted using the Benjamini-Hochberg method

(Fig.3c; Supplementary Table 4).

It is noted that we opted to perform all UK Biobank analyses on left eye data. This is because, as per

study protocol[55], the left eye was tested after the right eye, potentially making the measurements from

the left side less prone to artifacts (as the participants were more familiar with the test).

Additional analysis in the University Hospital of Bordeaux albinism cohort

Further analyses were undertaken using only data from individuals in the University Hospital of

Bordeaux albinism cohort. After excluding study subjects who did not report having European-like

ancestries, the cohort was split into cases with and cases without a molecular diagnosis of albinism

(*i.e.* "solved" and "unsolved"). Individuals without a molecular diagnosis who carried heterozygous

pathogenic or likely pathogenic variants in the *TYR* or *OCA2* gene (with the exception of the two

studied changes *TYR*:c.1205G>A and *OCA2*:c.1327G>A) were then removed from the unsolved

group. The patterns observed in genotype groups A-D were then assessed using both contingency

table methods and Firth regression analyses (Supplementary Table 7).

Ethics approval

Informed consent was obtained from all participants or their parents in the case of minors. The study

of individuals from the University Hospital of Bordeaux albinism cohort has been approved by the

relevant local ethics committee (Comité de Protection des Personnes Sud-Ouest et Outre Mer III,

Bordeaux, France). The informed consent process for the Genomics England 100,000 Genomes

Project has been approved by the National Research Ethics Service Research Ethics Committee for

East of England – Cambridge South Research Ethics Committee. The UK Biobank has received

approval from the National Information Governance Board for Health and Social Care and the

National Health Service North West Centre for Research Ethics Committee (Ref: 11/NW/0382). All

investigations were conducted in accordance with the tenets of the Declaration of Helsinki.

DATA AVAILABILITY

The Genomics England 100,000 Genomes Project dataset is available under

restricted access through a procedure described at

https://www.genomicsengland.co.uk/about-gecip/for-gecip-members/data-and-data-

access. The UK Biobank dataset is available under restricted access through a

procedure described at http://www.ukbiobank.ac.uk/using-the-resource/. All other

data supporting the findings of this study are available within the article (including its

Supplementary Information files).

CODE AVAILABILITY

The scripts used to analyse the datasets included in this study are available

at https://github.com/davidjohngreen/tyr-oca2.

REFERENCES

1. Boycott, K.M. *et al*. A diagnosis for all rare genetic diseases: The horizon and the next frontiers. *Cell*. **177**, 32-37 (2019). doi: 10.1016/j.cell.2019.02.040.
2. Splinter, K. *et al*. Effect of genetic diagnosis on patients with previously undiagnosed disease. *N Engl J Med*. **379**, 2131-2139 (2018). doi: 10.1056/NEJMoa1714458.
3. Posey, J.E. *et al*. Insights into genetics, human biology and disease gleaned from family based genomic studies. *Genet Med*. **21**, 798-812 (2019). doi: 10.1038/s41436-018-0408-7.
4. Zurek, B. *et al*. Solve-RD: systematic pan-European data sharing and collaborative analysis to solve rare diseases. *Eur J Hum Genet*. **29**, 1325-1331 (2021). doi: 10.1038/s41431-021-00859-0
5. 100,000 Genomes Project Pilot Investigators. 100,000 Genomes Pilot on rare-disease diagnosis in health care - Preliminary report. *N Engl J Med*. **385**, 1868-1880 (2021). doi: 10.1056/NEJMoa2035790.
6. Boycott, K.M. *et al*. Care4Rare Canada: Outcomes from a decade of network science for rare disease gene discovery. *Am J Hum Genet*. **109**, 1947-1959 (2022). doi: 10.1016/j.ajhg.2022.10.002.
7. Schäffer, A.A. Digenic inheritance in medical genetics. *J Med Genet*. **50**, 641-652 (2013). doi: 10.1136/jmedgenet-2013-101713.
8. Katsanis, N. The continuum of causality in human genetic disorders. *Genome Biol*. **17**, 233 (2016). doi: 10.1186/s13059-016-1107-9.
9. Deltas C. Digenic inheritance and genetic modifiers. *Clin Genet*. **93**, 429-438 (2018). doi: 10.1111/cge.13150.
10. Nachtegael, C. *et al*. Scaling up oligogenic diseases research with OLIDA: the Oligogenic Diseases Database. *Database (Oxford)*. **2022**, baac023 (2022). doi: 10.1093/database/baac023.
11. Burkard, M. *et al*. Accessory heterozygous mutations in cone photoreceptor CNGA3 exacerbate CNG channel-associated retinopathy. *J Clin Invest*. **128**, 5663-5675 (2018). doi: 10.1172/JCI96098
12. Cooper, D.N., Krawczak, M., Polychronakos, C., Tyler-Smith, C. & Kehrer-Sawatzki, H. Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease. *Hum Genet*. **132**, 1077-1130 (2013). doi: 10.1007/s00439-013-1331-2.
13. Kousi, M. & Katsanis, N. Genetic modifiers and oligogenic inheritance. *Cold Spring Harb Perspect Med*. **5**, a017145 (2015). doi: 10.1101/cshperspect.a017145.
14. Costanzo, M. *et al*. Global genetic networks and the genotype-to-phenotype relationship. *Cell*. **177**, 85-100 (2019). doi: 10.1016/j.cell.2019.01.033.
15. Mukherjee, S. *et al*. Identifying digenic disease genes via machine learning in the Undiagnosed Diseases Network. *Am J Hum Genet*. **108**, 1946-1963 (2021). doi: 10.1016/j.ajhg.2021.08.010.
16. Papadimitriou, S. *et al*. Predicting disease-causing variant combinations. *Proc Natl Acad Sci U S A*. **116**:11878-11887 (2019). doi: 10.1073/pnas.1815601116.
17. Brehm, A. *et al*. Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production. *J Clin Invest*. **125**, 4196-4211 (2015). doi: 10.1172/JCI81260.
18. Bakker, R. *et al*. The retinal pigmentation pathway in human albinism: Not so black and white. *Prog Retin Eye Res*. **91**, 101091 (2022). doi: 10.1016/j.preteyeres.2022.101091.
19. Michaud, V. *et al*. The contribution of common regulatory and protein-coding TYR variants to the genetic architecture of albinism. *Nat Commun*. **13**, 3939 (2022). doi: 10.1038/s41467-022-31392-3.
20. Campbell, P. *et al*. Clinical and genetic variability in children with partial albinism. *Sci Rep*. **9**, 16576 (2019). doi: 10.1038/s41598-019-51768-8.
21. Monfermé, S. *et al*. Mild form of oculocutaneous albinism type 1: phenotypic analysis of compound heterozygous patients with the R402Q variant of the *TYR* gene. *Br J Ophthalmol*. **103**, 1239-1247 (2019). doi: 10.1136/bjophthalmol-2018-312729
22. Lasseaux, E. *et al*. Molecular characterization of a series of 990 index patients with albinism. *Pigment Cell Melanoma Res*. **31**, 466-474 (2018). doi: 10.1111/pcmr.12688.
23. Caulfield, M. *et al*. The National Genomic Research Library. https://doi.org/10.6084/m9.figshare.4530893.v7 (2017).

24. Okazaki, A. & Ott, J. Machine learning approaches to explore digenic inheritance. *Trends*
Genet. **38**, 1013-1018 (2022). doi: 10.1016/j.tig.2022.04.009.
25. Jagirdar, K. *et al*. Molecular analysis of common polymorphisms within the human tyrosinase
locus and genetic association with pigmentation traits. *Pigment Cell Melanoma Res*. **27**, 552-
564 (2014). doi: 10.1111/pcmr.12253.
26. Dolinska, M.B. *et al*. Oculocutaneous albinism type 1: link between mutations, tyrosinase
conformational stability, and enzymatic activity. Pigment Cell Melanoma Res. **30**, 41-52
(2017). doi: 10.1111/pcmr.12546.
27. Sviderskaya, E.V. *et al*. Complementation of hypopigmentation in p-mutant (pink-eyed
dilution) mouse melanocytes by normal human P cDNA, and defective complementation by
OCA2 mutant sequences. *J Invest Dermatol*. **108**, 30-34 (1997). doi: 10.1111/1523-
1747.ep12285621
28. Bellono, N.W., Escobar, I.E., Lefkovith, A.J., Marks, M.S. & Oancea, E. An intracellular anion
channel critical for pigmentation. *Elife*. **3**, e04543 (2014). doi: 10.7554/eLife.04543.
29. Bellono, N.W., Escobar, I.E. & Oancea, E. A melanosomal two-pore sodium channel
regulates pigmentation. *Sci Rep*. **6**, 26570 (2016). doi: 10.1038/srep26570.
30. Pavan W.J. & Sturm, R.A. The genetics of human skin and hair pigmentation. *Annu Rev*
Genomics Hum Genet. **20**, 41-72 (2019). doi: 10.1146/annurev-genom-083118-015230.
31. Landrum, M.J. *et al*. ClinVar: improving access to variant interpretations and supporting
evidence. *Nucleic Acids Res*. **46**, D1062-D1067 (2018). doi: 10.1093/nar/gkx1153.
[accessions VCV000003779.25 & VCV000000955.52].
32. Buniello, A. *et al*. The NHGRI-EBI GWAS Catalog of published genome-wide association
studies, targeted arrays and summary statistics 2019. *Nucleic Acids Res*. **47**, D1005-D1012
(2019). doi: 10.1093/nar/gky1120. [entries for rs1126809 and rs74653330]
33. Karczewski, K.J. *et al*. The mutational constraint spectrum quantified from variation in
141,456 humans. *Nature*. **581**, 434-443 (2020). doi: 10.1038/s41586-020-2308-7.
[entries for 11-89017961-G-A (GRCh37) and 15-28228553-C-T (GRCh37)]
34. Loftus, S.K. *et al*. Haplotype-based analysis resolves missing heritability in oculocutaneous
albinism type 1B. *Am J Hum Genet*. **S0002-9297**, 00169-6 (2023). doi:
10.1016/j.ajhg.2023.05.012.
35. Lin, S., *et al*. Evidence that the Ser192Tyr/Arg402Gln in *cis* Tyrosinase gene haplotype is a
disease-causing allele in oculocutaneous albinism type 1B (OCA1B). *NPJ Genom Med*. **7**, 2
(2022). doi: 10.1038/s41525-021-00275-9.
36. Grønskov, K. *et al*. A pathogenic haplotype, common in Europeans, causes autosomal
recessive albinism and uncovers missing heritability in OCA1. *Sci Rep*. **9**, 645 (2019). doi:
10.1038/s41598-018-37272-5.
37. Heinze, G. & Schemper, M. A solution to the problem of separation in logistic regression. *Stat*
Med. **21**, 2409-19 (2002). doi: 10.1002/sim.1047.
38. Firth, D. Bias reduction of maximum likelihood estimates. *Biometrika*. **80**, 27-38 (1993). doi:
10.1093/biomet/80.1.27
39. Marchini, J., Cardon, L.R., Phillips, M.S. & Donnelly, P. The effects of human population
structure on large genetic association studies. *Nat Genet*. **36**, 512–517 (2004). doi:
10.1038/ng1337
40. Bycroft, C. *et al*. The UK Biobank resource with deep phenotyping and genomic data. *Nature*.
562, 203-209 (2018). doi: 10.1038/s41586-018-0579-z.
41. Masson, E. *et al*. Expanding ACMG variant classification guidelines into a general framework.
Hum Genomics. **16**, 31 (2022). doi: 10.1186/s40246-022-00407-x.
42. Richards, S. *et al*. Standards and guidelines for the interpretation of sequence variants: a joint
consensus recommendation of the American College of Medical Genetics and Genomics and
the Association for Molecular Pathology. *Genet Med*. **17**, 405-424 (2015). doi:
10.1038/gim.2015.30.
43. Freedman, M.L. *et al*. Assessing the impact of population stratification on genetic association
studies. *Nat Genet*. **36**, 388-93 (2004). doi: 10.1038/ng1333.
44. Devlin, B. & Roeder, K. Genomic control for association studies. *Biometrics*. **55**, 997-1004
(1999). doi: 10.1111/j.0006-341x.1999.00997.x
45. Dadd, T., Weale, M.E. & Lewis, C.M. A critical evaluation of genomic control methods for
genetic association studies. *Genet Epidemiol*. **33**, 290-298 (2009). doi: 10.1002/gepi.20379.
46. Turnbull, C. *et al*. The 100,000 Genomes Project: bringing whole genome sequencing to the
NHS. *BMJ* **361**, 1687 (2018). doi: 10.1136/bmj.k1687

47. Köhler, S. *et al.* The Human Phenotype Ontology in 2021. *Nucleic Acids Res.* **49**, D1207–
D1217 (2021). doi: 10.1093/nar/gkaa1043
48. Raczy, C. *et al.* Isaac: ultra-fast whole-genome secondary analysis on Illumina sequencing
platforms. *Bioinformatics* **29**, 2041–2043 (2013). doi: 10.1093/bioinformatics/btt314.
49. Chen, X., *et al.* Manta: rapid detection of structural variants and indels for germline and
cancer sequencing applications. *Bioinformatics* **32**, 1220-1222 (2016). doi:
10.1093/bioinformatics/btv710.
50. Roller, E., Ivakhno, S., Lee, S., Royce, T. & Tanner, S. Canvas: versatile and scalable
detection of copy number variants. *Bioinformatics* **32**, 2375-2377 (2016). doi:
10.1093/bioinformatics/btw163.
51. Tan, A., Abecasis, G.R. & Kang, H.M. Unified representation of genetic variants.
Bioinformatics **31**, 2202–2204 (2015). doi: 10.1093/bioinformatics/btv112
52. Danecek, P. *et al.* Twelve years of SAMtools and BCFtools. *Gigascience* **10**, giab008 (2021).
53. McLaren, W. *et al.* The Ensembl Variant Effect Predictor. *Genome Biol.* **17**, (2016). doi:
10.1186/s13059-016-0974-4
54. Stenson, P.D. *et al.* The Human Gene Mutation Database (HGMD®): optimizing its use in a
clinical diagnostic or research setting. *Hum Genet*. **139**, 1197-1207 (2020). doi:
10.1007/s00439-020-02199-3.
55. Chua, S.Y.L., *et al.* Cohort profile: design and methods in the eye and vision consortium of
UK Biobank. *BMJ Open* **9**, e025077 (2019).
56. Bouma, B.E. *et al*. Optical coherence tomography. *Nat Rev Methods Primers*. **2,** 79 (2022).
doi: 10.1038/s43586-022-00162-2.
57. Drexler, W. & Fujimoto, J.G. State-of-the-art retinal optical coherence tomography. *Prog Retin
Eye Res*. **27**, 45–88 (2008). doi: 10.1016/j.preteyeres.2007.07.005
58. Currant, H. *et al*. Genetic variation affects morphological retinal phenotypes extracted from
UK Biobank optical coherence tomography images. *PLoS Genet*. **17**, e1009497 (2021). doi:
10.1371/journal.pgen.1009497
625

628 **ACKNOWLEDGEMENTS**
629

We acknowledge the following sources of funding: the Wellcome Trust

(224643/Z/21/Z, Clinical Research Career Development Fellowship to P.I.S.;

200990/Z/16/Z, Transforming Genetic Medicine Initiative to G.C.B.); the UK National

Institute for Health Research (NIHR) Clinical Lecturer Programme (CL-2017-06-001

to P.I.S.); Retina UK and Fight for Sight (GR586, RP Genome Project - UK Inherited

Retinal Disease Consortium to G.C.B.); Christopher Green (D.J.G.); the French

Albinism Association (Genespoir) and the French National Research Agency

(Agence Nationale de la Recherche; ANR-21-CE17-0041-01 to B.A.).

The UK Biobank Eye and Vision Consortium is supported by funding from the NIHR

Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of

Ophthalmology, the Alcon Foundation and the Desmond Foundation. The complete

list of members of this Consortium can be found in the Supplementary Information

This research was made possible through access to the data and findings generated

by the 100,000 Genomes Project. The 100,000 Genomes Project is managed by

Genomics England Limited (a wholly owned company of the Department of Health

and Social Care). The 100,000 Genomes Project is funded by the NIHR and NHS

England. The Wellcome Trust, Cancer Research UK and the Medical Research

Council have also funded research infrastructure. The 100,000 Genomes Project

uses data provided by patients and collected by the National Health Service (NHS)

as part of their care and support. We acknowledge the contribution of the Genomics

England Research Consortium to the 100,000 Genomes Project. The complete list of

members of this Consortium can be found in the Supplementary Information.

Lastly, we acknowledge the help of Cécile Courdier at the University Hospital of

Bordeaux Molecular Genetics Laboratory, Sophie Javerzat at the University of

Bordeaux, Dave Gerrard at the University of Manchester, and Claire Hardcastle,

Chris Campbell, Steph Barton and Simon Ramsden at the North West of England

Genomic Laboratory Hub.

AUTHOR CONTRIBUTIONS STATEMENT

P.I.S. conceived and designed the experiments. The UK Biobank Eye and Vision

Consortium, T.F., E.B., B.A., G.C.B. and P.I.S provided datasets and analytical tools.

D.J.G., V.M., E.L., C.P., T.F., B.A. and P.I.S. analysed the data. P.I.S. wrote the

manuscript with support from D.J.G. All authors critically revised and approved the

manuscript.

G.C.B. and B.A. contributed equally to this work.

COMPETING INTERESTS STATEMENT

E.B. is a paid consultant and equity holder of Oxford Nanopore, a paid consultant to

Dovetail, and a non-executive director of Genomics England, a limited company

wholly owned by the UK Department of Health and Social Care. All other authors

declare no competing interests.